Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TAFINLAR DISPERSIBLE TABLET 10MG - HSA Drug Approval Details

Approvals/HSA/TAFINLAR DISPERSIBLE TABLET 10MG

Approved

THERAPEUTIC

TAFINLAR DISPERSIBLE TABLET 10MG

Novartis Pharma Stein AG🇸🇬 Health Sciences Authority

Approval Date: Jun 3, 2024
Approval ID: a8226ed9f3cc23d1
Company: Novartis Pharma Stein AG
Type: Therapeutic

Approval Details

Approval Id: a8226ed9f3cc23d1
Drug Name: TAFINLAR DISPERSIBLE TABLET 10MG
Product Name: TAFINLAR DISPERSIBLE TABLET 10MG
Approval Number: SIN17019P
Approval Date: 2024-06-03
Registrant: NOVARTIS (SINGAPORE) PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET, FOR SUSPENSION
Route Of Administration: ORAL
Atc Code: L01EC02
Pharma Manufacturer Name: NOVARTIS (SINGAPORE) PTE LTD
Company Detail Path: /organization/b4e5c80b52263481/novartis-singapore-pte-ltd

Active Ingredients

Dabrafenib mesylate eqv Dabrafenib

10mg

Dabrafenib mesylate eqv Dabrafenib

10mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jun 3, 2024

Approval ID

a8226ed9f3cc23d1

Type

Therapeutic

Back to HSA Approvals